Identification of
small-molecule-binding sites in protein is important
for drug discovery and analysis of protein function. Modified amino-acid
residue(s) can be identified by proteolytic cleavage followed by liquid
chromatography–mass spectrometry (LC–MS), but this is
often hindered by the complexity of the peptide mixtures. We have
developed alkyne-tag Raman screening (ATRaS) for identifying binding
sites. In ATRaS, small molecules are tagged with alkyne and form covalent
bond with proteins. After proteolysis and HPLC, fractions containing
the labeled peptides with alkyne tags are detected by means of surface-enhanced
Raman scattering (SERS) using silver nanoparticles and sent to MS/MS
to identify the binding site. The use of SERS realizes high sensitivity
(detection limit: ∼100 femtomole) and reproducibility in the
peptide screening. By using an automated ATRaS system, we successfully
identified the inhibitor-binding site in cysteine protease cathepsin
B, a potential drug target and prognostic marker for tumor metastasis.
We further showed that the ATRaS system works for complex mixtures
of trypsin-digested cell lysate. The ATRaS technology, which provides
high molecular selectivity to LC–MS analysis, has potential
to contribute in various research fields, such as drug discovery,
proteomics, metabolomics and chemical biology.